Reeves J D, Driggers D A, Lo E Y, Dallman P R
J Pediatr. 1981 Jun;98(6):894-8. doi: 10.1016/s0022-3476(81)80581-1.
Initial screening for anemia was performed on a capillary blood sample in 800 apparently healthy one-year-old white infants. Twenty-six percent had a Hgb or MCV below the estimated tenth percentile of normal and were asked to return for blood counts on a venous sample. They were then started on a three-month course of oral iron. Of the 151 infants who satisfactorily completed the treatment regimen, 54 had a greater than or equal to 1 gm/dl rise in venous Hgb (2.8 infants treated/response). If conformation of the capillary by the venous values had been a prerequisite for treatment, the size of the treatment group would have decreased from 151 to 87, the response rate would have been improved to 2.0 infants treated per response, but 11 of the infants who had a greater than or equal to 1 gm/dl response would have been missed. Since toxicity from iron therapy is rare, either the use of capillary blood counts alone or in combination with venous values constitutes a satisfactory basis for a therapeutic trial of iron in similar populations. Further evaluation can then be reserved for the small number whose Hgb remains below the lower limit of normal after treatment.
对800名看似健康的一岁白人婴儿采集毛细血管血样本进行贫血初步筛查。26%的婴儿血红蛋白(Hgb)或平均红细胞体积(MCV)低于正常估计的第十百分位数,被要求返回采集静脉血样本进行血细胞计数。然后他们开始接受为期三个月的口服铁剂疗程。在151名圆满完成治疗方案的婴儿中,54名婴儿的静脉血红蛋白升高大于或等于1克/分升(每2.8名接受治疗的婴儿有1例有反应)。如果以静脉血值来确认毛细血管血值作为治疗的前提条件,治疗组的规模将从151名减少到87名,反应率将提高到每例有反应的婴儿对应2.0名接受治疗的婴儿,但11名血红蛋白升高大于或等于1克/分升的婴儿将会被遗漏。由于铁剂治疗的毒性罕见,单独使用毛细血管血细胞计数或与静脉血值结合使用,都构成了在类似人群中进行铁剂治疗试验的满意依据。然后可以对治疗后血红蛋白仍低于正常下限的少数人进行进一步评估。